COVID-19 presents in serious cases with hyperinflammation throughout multiple organs. Biotherapeutics have the potential to elicit an immune response that can alter or neutralize the efficacy of the therapeutic, which in many cases -- including oncology and enzyme replacement therapy -- are lifesaving. The effects of the changed immune state in COVID-19 patients on the immunogenicity to these biotherapeutics remain largely undiscovered.